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BMT and no vaccine-related serious adverse events occurred. Nei-
ther allo or autologous transplant recipients had demonstrable an-
tibodies against pertussis 1 year following BMT and immunogenic-
ity of the pertussis component of Tdap was poor, even following
3 doses, despite good immune responses to Td. While a correlate
of protection from pertussis is not known, observed responses to
Tdap following both allo and auto BMT raise concern that even a
3-dose series of Tdap may not provide full protection in this popu-
lation. Further studies are needed to establish optimal immuniza-
tion timing and schedule of Tdap required to ensure protection in
this vulnerable population.
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Background: Varciella Zoster Virus (VZV) can lead to serious com-
plications in Hematopoietic Cell Transplant (HCT) recipients. Cen-
tral nervous system (CNS) VZV can be one of the most devastating
infections in transplant recipients, yet little is known about this
rare disease.
Objectives: To describe CNS VZV in the post-transplant period and
to define potential risk factors in the HCT population.
Methods: We reviewed the course of all patients who received a
first HCT at the Fred Hutchinson Cancer Center (FHCRC) in Seat-
tle, WA from 1/1996 through 12/2007. Data were collected retro-
spectively using the Long-Term Follow-Up database, which includes
on-site examinations, outside records, laboratory tests, and yearly
questionnaires. Patients were classified as CNS VZV if they had lab-
oratory confirmation of VZV in the cerebrospinal fluid (CSF), or had
zoster with associated clinical and laboratory findings consistent
with CNS disease.
Results: A total of six patients developed VZV CNS disease during
the evaluation period (table 1). Diagnosis was confirmed in 3/6 by
detection of VZV in CSF by PCR. All other patients had a clinical
diagnosis based on the presence of CNS symptoms, zoster, lympho-
cytic pleiocytosis, and response to IV acyclovir. Patients who devel-
oped CNS disease had a mean age of 42 years (range 34-51) at time
of transplant. CNS disease developed at a mean of 9 months post-
transplantation (range 0.5–24 months), and severity varied, rang-
ing from meningitis (3/6) to encephalitis/myelitis (3/6). All had
active graft-versus host disease (GHVD) and all were being treated
with immunosuppressive therapy at time of diagnosis. Fever and
headache were the most common symptoms, but patients who de-
veloped focal CNS findings or seizures (3/6) had a more compli-
cated clinical course. While most patients presented with classic
Abstract 47 – Table 1. Varicella zoster virus CNS disease case descriptions
Age Onset Severity Symptoms/Signs Skin Rash MRI Findings LP findings Outcome
37 F Day +153 VZE Neck stiffness, Yes Tentorial and trigeminal ↑protein, lymphs Death, 6.2 months
Encephalopathy, seizures cave enchancement VZE
34 M 24 months Meningitis Headache, neck stiffness, fever Yes None ↑protein, lymphs Alive
52 F Day +83 Meningitis Headache, neck stiffness, No None ↑protein, lymphs Death, 4.1 months
dizziness, fever Aspergillus pneumonia
41 F Day +15 VZE Headache, fever, seizures No None – Death, 5.4 months
Recurrent-ALL
45 M 18 months Meningitis Headache, fevers Yes Bilateral small infarcts ↑protein, lymphs Alive
42 M Day +236 Myelitis Fever, LE numbness Yes Hemorrhagic encephalo-myelitis – Death, 14.5 months
Persistent quadriplegia,
Pulmonary Embolus
VZV/zoster skin lesions, 2/6 patients had no dermatologic findings
associated with their presentation. Four (66%) of patients who de-
veloped VZV CNS disease died, two related to VZV complications
despite aggressive antiviral therapy.
Conclusions: In this cohort of HCT patients, VZV CNS disease was a
rare complication. Mortality due to CNS VZV is high, particularly in
patients who develop focal neurologic findings or seizures. Even in
the absence of skin lesions, VZV CNS disease should be considered
in patients who develop fevers and neurologic symptoms.
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Objective: The aim of the research was a detailed study and anal-
ysis of current data and trends of HIV/AIDS epidemiology in one
of the largest areas in Central Russia in order to show the grow-
ing need for treatment and palliative care for people living with
HIV/AIDS in the region.
Methods: We studied the official demographical data and the
HIV/AIDS epidemiology data provided by the regional AIDS Cen-
tre within the entire period of epidemic and compared it with the
official federal statistics.
Results: As for January 2007, the cumulative number of regis-
tered HIV cases was 4,870. The actual number of people living
with HIV/AIDS is increasing and faster than registered over the last
year or two. It is likely that 17,000 - 22,000 people are living with
HIV/AIDS in the region. Young people aged 15 to 29 comprise 85.5%
of all registered HIV cases. HIV infection was attributed to injection
drug use in 73.5% of all registered cases. Since 2002, experts have
identified an increase in sexual transmission. In 2006, 49.3% of all
registered cases were attributed to sexual contact. Today far more
of the HIV-positive individuals are men (56.9%). The most recent
and negative trend is the proportion of women infected which has
been increasing. In 2006, the proportion of women among newly
diagnosed HIV cases was 43.7%. As a result, there is an increase
in the potential for a growing mother-to-child HIV transmission.
The problem is becoming worse as HIV spreads more widely from
vulnerable groups into the general population.
Conclusion: This study demonstrates the major trends in HIV/AIDS
epidemic progression and can be used for making estimates and
helping policymakers to determine the impact of specific programs
in the region.
